A novel family of 1,3,5-trisubstituted 1,2,4-triazoles was discovered as potent and selective ligands for the delta opioid receptor by rational design. Compound 5b exhibited low-nanomolar in vitro binding affinity (IC50 = 5.8 nM), excellent selectivity for the d opioid receptor over the alternative mu and kappa opioid receptors, full agonist efficacy in receptor down-regulation and MAP kinase activation assays, and low-efficacy partial agonist activity in stimulation of GTP gamma S binding. The apparent discrepancy observed in these functional assays may stem from different signaling pathways involved in each case, as found previously for other G-protein coupled receptors. More biological studies are underway to better understand the differential stimulation of signaling pathways by these novel compounds. (C) 2009 Elsevier Ltd. All rights reserved.
Opioid receptor compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a condition mediated by an opioid receptor by administering an effective amount of the opioid receptor compound to a patient in need thereof.
US8188128B2
申请人:——
公开号:US8188128B2
公开(公告)日:2012-05-29
[EN] OPIOID RECEPTOR SUBTYPE-SELECTIVE AGENTS<br/>[FR] AGENTS SELECTIFS EN FONCTION DU SOUS-TYPE DE RECEPTEURS D'OPIATES
申请人:UNIV NEW JERSEY MED
公开号:WO2006124687A1
公开(公告)日:2006-11-23
[EN] Opioid receptor compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a condition mediated by an opioid receptor by administering an effective amount of the opioid receptor compound to a patient in need thereof. [FR] L'invention concerne des composés à base de récepteurs d'opiatés et des compositions pharmaceutiques correspondantes. Elle concerne également des procédés pour traiter un état à médiation par un récepteur d'opiatés, qui consistent à administrer une quantité efficace du composé de récepteurs d'opiatés à un patient que le nécessite.